MDxHealth (MDXH) Stock Price, News & Analysis

Company Overview

MDxHealth SA (NASDAQ: MDXH) is a molecular diagnostics company focused on helping physicians make more informed decisions in cancer care. The company develops and commercializes genomic and epigenetic tests designed to support cancer detection, diagnosis, prognosis and treatment planning.

MDxHealth’s portfolio has primarily centered on prostate cancer. Its ConfirmMDx test analyzes prostate tissue to help identify patients who may have clinically significant cancer despite an initially negative biopsy, while SelectMDx is a urine-based test intended to help assess the likelihood of clinically significant prostate cancer and guide decisions about biopsy. The company has also developed diagnostic solutions for other areas of oncology and continues to expand its precision-medicine offerings.

Founded in Belgium and formerly known as OncoMethylome Sciences, MDxHealth serves healthcare providers and patients through operations in the United States and Europe. The company maintains laboratory and commercial activities in the U.S. and Europe, with its corporate headquarters in Irvine, California. Its leadership has included Michael McGarrity as chief executive officer.

Key Stats

• Today's Range: $0.15 to $0.18
• 50-Day Range: $0.16 to $0.79
• 52-Week Range: $0.15 to $4.83
• Volume: 437,809 shs
• Average Volume: 2.18 million shs
• Market Capitalization: $7.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.33
• Consensus Rating: Hold

MDxHealth Stock Analysis - MarketRank™

MDxHealth scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

MDxHealth has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.

Upside Potential

MDxHealth has a consensus price target of $1.33, representing about 749.3% upside from its current price of $0.16.

Amount of Analyst Coverage

MDxHealth has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MDxHealth are expected to grow in the coming year, from ($0.49) to ($0.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MDxHealth is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MDxHealth is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.45% of the float of MDxHealth has been sold short.

Short Interest Ratio / Days to Cover

MDxHealth has a short interest ratio ("days to cover") of 4.86.

Change versus previous month

Short interest in MDxHealth has recently decreased by 11.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MDxHealth does not currently pay a dividend.

Dividend Growth

MDxHealth does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.24

News Sentiment

MDxHealth has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for MDxHealth this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added MDxHealth to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MDxHealth insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of MDxHealth is held by insiders.

Percentage Held by Institutions

MDxHealth has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MDXH
• CIK: 1872529
• Web: mdxhealth.com
• Phone: 324-364-2070
• Fax: 32042597875
• Employees: 364
• Year Founded: 2003

Price Target and Rating

• Average Price Target for MDxHealth: $1.33
• High Price Target: $2.00
• Low Price Target: $0.50
• Potential Upside/Downside: +749.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.52 million
• Net Margins: -33.46%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -24.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $107.88 million
• Price / Sales: 0.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.24) per share
• Price / Book: -0.65

Miscellaneous

• Outstanding Shares: 49,500,000
• Free Float: 48,656,000
• Market Cap: $7.77 million
• Optionable: Not Optionable
• Beta: 1.81